IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

ÉVRY, France and LUXEMBOURG City, Luxembourg (February 27th, 2019) – IntegraGen, a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, and Advanced Biological Laboratories (ABL), a leading integrated diagnostics and medical IT company, announced today the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked  diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

See the related Press Release